PURE Bioscience to Present at the B. Riley & Co. 18th Annual Investor Conference

SAN DIEGO--()--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will present at the B. Riley & Co. 18th Annual Investor Conference on May 25, 2017, at the Lowes Santa Monica Hotel in Santa Monica, CA.

Hank R. Lambert, CEO of PURE, will present at 10:00am PDT and provide business updates on the Company’s two food safety antimicrobials:

  • PURE® Hard Surface disinfectant
    • Recent sales to Chipotle Mexican Grill and other restaurants, and expanding use with +40 national food processors
    • Presently +$2 million annualized revenue run rate
  • PURE Control® (FDA approved direct food contact processing aid)
    • Sales & marketing to fresh produce processors; first order received in April
    • Progress of USDA in-plant trials for approval for raw poultry processing
    • SDC test results demonstrate materially significant reduction in Salmonella, Listeria and E. coli contamination in fresh produce; and dramatic reduction of Salmonella contamination in raw poultry.
    • Est. combined +$650 million U.S. market opportunity for produce and poultry processing aids

The presentation will be webcast live with slides (and available for replay) and can be accessed at: http://www.wsw.com/webcast/brileyco18/pure.

About B. Riley & Co., LLC

B. Riley & Co., LLC is a leading investment bank providing advisory, research, and sales & trading to corporate, institutional and high net worth individual clients. Investment banking services include M&A advisory and debt and equity offerings. The firm is nationally recognized for its highly ranked proprietary equity research. B. Riley & Co. is a member of FINRA and SIPC. For more information, please visit www.brileyco.com.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena – providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2016 and second quarter ended January 31, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts

PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600, ext. 103
hlambert@purebio.com
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
terri@bibimac.com
or
Redwood Investment Group
Tom Hemingway
714-978-4425
tomh@redwoodfin.com

Recent Stories

RSS feed for PURE Bioscience, Inc.

PURE Bioscience, Inc.